The M. D. Anderson proton therapy system

被引:157
|
作者
Smith, Alfred [1 ,2 ]
Gillin, Michael [1 ,2 ]
Bues, Martin [1 ,2 ]
Zhu, X. Ronald [1 ,2 ]
Suzuki, Kazumichi [1 ,2 ]
Mohan, Radhe [1 ,2 ]
Woo, Shiao [1 ,2 ]
Lee, Andrew [1 ,2 ]
Komaki, Ritsko [1 ,2 ]
Cox, James [1 ,2 ]
Hiramoto, Kazuo [3 ]
Akiyama, Hiroshi [4 ]
Ishida, Takayuki [4 ]
Sasaki, Toshie [4 ]
Matsuda, Koji [4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[3] Hitachi Ltd, Energy & Environm Syst Lab, Hitachi, Ibaraki 3191221, Japan
[4] Hitachi Ltd, Hitachi Works, Power Syst, Hitachi, Ibaraki 3178511, Japan
关键词
proton therapy; proton therapy physics; proton therapy technology; proton therapy facilities; BEAM RADIOTHERAPY; CHOROIDAL MELANOMA; UVEAL MELANOMA; CENTER-HOUSTON; EYE;
D O I
10.1118/1.3187229
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study is to describe the University of Texas M. D. Anderson proton therapy system (PTC-H) including the accelerator, beam transport, and treatment delivery systems, the functionality and clinical parameters for passive scattering and pencil beam scanning treatment modes, and the results of acceptance tests. Methods: The PTC-H has a synchrotron (70-250 MeV) and four treatment rooms. An overall control system manages the treatment, physics, and service modes of operation. An independent safety system ensures the safety of patients, staff, and equipment. Three treatment rooms have isocentric gantries and one room has two fixed horizontal beamlines, which include a large-field treatment nozzle, used primarily for prostate treatments, and a small-field treatment nozzle for ocular treatments. Two gantry treatment rooms and the fixed-beam treatment room have passive scattering nozzles. The third gantry has a pencil beam scanning nozzle for the delivery of intensity modulated proton treatments (IMPT) and single field uniform dose (SFUD) treatments. The PTC-H also has an experimental room with a fixed horizontal beamline and a passive scattering nozzle. The equipment described above was provided by Hitachi, Ltd. Treatment planning is performed using the Eclipse system from Varian Medical Systems and data management is handled by the MOSAIQ system from IMPAC Medical Systems, Inc. The large-field passive scattering nozzles use double scattering systems in which the first scatterers are physically integrated with the range modulation wheels. The proton beam is gated on the rotating range modulation wheels at gating angles designed to produce spread-out-Bragg peaks ranging in size from 2 to 16 g/cm(2). Field sizes of up to 25 X 25 cm(2) can be achieved with the double scattering system. The IMPT delivery technique is discrete spot scanning, which has a maximum field size of 30 X 30 cm(2). Depth scanning is achieved by changing the energy extracted from the synchrotron (energy can be changed pulse to pulse). The PTC-H is fully integrated with DICOM-RT ION interfaces for imaging, treatment planning, data management, and treatment control functions. Results: The proton therapy system passed all acceptance tests for both passive scattering and pencil beam scanning. Treatments with passive scattering began in May 2006 and treatments with the scanning system began in May 2008. The PTC-H was the first commercial system to demonstrate capabilities for IMPT treatments and the first in the United States to treat using SFUD techniques. The facility has been in clinical operation since May 2006 with up-time of approximately 98%. Conclusions: As with most projects for which a considerable amount of new technology is developed and which have duration spanning several years, at project completion it was determined that several upgrades would improve the overall system performance. Some possible upgrades are discussed. Overall, the system has been very robust, accurate, reproducible, and reliable. The authors found the pencil beam scanning system to be particularly satisfactory; prostate treatments can be delivered on the scanning nozzle in less time than is required on the passive scattering nozzle. (C) 2009 American Association of Physicists in Medicine. [DOI: 10.1118/1.3187229]
引用
收藏
页码:4068 / 4083
页数:16
相关论文
共 50 条
  • [41] LIPOSARCOMA OF THE HEAD AND NECK: THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER EXPERIENCE
    Davis, Erica C.
    Ballo, Matthew T.
    Luna, Mario A.
    Patel, Shreyakurnar R.
    Roberts, Dianna B.
    Nong, Xiaolin
    Sturgis, Erich M.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2009, 31 (01): : 28 - 36
  • [42] Rehabilitation of surgical cancer patients at University of Texas M. D. Anderson Cancer Center
    Yadav, Rajesh
    JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (05) : 361 - 369
  • [43] Is there a role for surgery in the management of metastatic urothelial cancer? An update of the M. D. Anderson experience
    Siefker-Radtke, A
    Walsh, GL
    Swanson, DA
    Logothetis, CJ
    Millikan, RE
    JOURNAL OF UROLOGY, 2002, 167 (04): : 283 - 283
  • [44] Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory
    Gning, Ibrahima
    Trask, Peter C.
    Mendoza, Tito R.
    Harle, Margaret T.
    Gutierrez, Karla A.
    Kitaka, Sheila A.
    Sherman, Steven I.
    Cleeland, Charles S.
    ONCOLOGY, 2009, 76 (01) : 59 - 68
  • [45] Adrenocortical carcinoma: The University of Texas M. D. Anderson Cancer Center experience update
    Ejaz, S.
    Jamal, S.
    Busaidy, N.
    Jimenez, C.
    Vassilopoulou-Sellin, R.
    Habra, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer
    Sailors, Mary H.
    Bodurka, Diane C.
    Gning, Ibrahima
    Ramondetta, Lois M.
    Williams, Loretta A.
    Mendoza, Tito R.
    Agarwal, Sonika
    Sun, Charlotte C.
    Cleeland, Charles S.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (02) : 323 - 328
  • [47] Initial development and validation of the thyroid cancer module of the M. D. Anderson symptom inventory
    Trask, P.
    Gning, I
    Mendoza, T.
    Harle, M.
    Gutierrez, K.
    Kitaka, S.
    Sherman, S.
    Cleeland, C.
    PSYCHO-ONCOLOGY, 2008, 17 (03) : S99 - S100
  • [48] Survival of patients in a phase I clinic: The M. D. Anderson Cancer Center experience
    Wheler, J. J.
    Tsimberidou, A. M.
    Hong, D. S.
    Jackson, T. L.
    Polk, D. Y.
    Pilat, S.
    Liu, S.
    Feng, L.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Radiologic-pathologic conferences of the University of Texas M. D. Anderson Cancer Center
    Avritscher, R
    Iyer, RB
    Ro, J
    Whitman, G
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2001, 177 (04) : 856 - 856
  • [50] Taiwanese version of the M. D. Anderson symptom inventory: Symptom assessment in cancer patients
    Lin, Chia-Chin
    Chang, Ai-Ping
    Cleeland, Charles S.
    Mendoza, Tito R.
    Wang, Xin Shelley
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 33 (02) : 180 - 188